LISTING OF CLAIMS

1. **(Currently amended)** A method of inhibiting unwanted cell proliferation comprising, determining whether cells overexpress a ~~*gli*~~ *gli-1* gene, and
contacting cells that overexpress a ~~*gli*~~ *gli-1* gene with an effective amount of ~~a hedgehog antagonist~~ a hedgehog antibody;
whereby said ~~antagonist~~ hedgehog antibody causes decreased cell proliferation.

2. **(Canceled)**

3. **(Currently amended)** ~~A~~ The method of claim 1, wherein said unwanted cell proliferation is cancer.

4. **(Withdrawn)** A method of claim 3, wherein said cancer is urogenital cancer.

5. **(Currently amended)** ~~A~~ The method of claim 3, wherein said cancer is associated with one or more of lung, prostate, breast, bladder, and colon tissues.

6. **(Withdrawn)** A method of claim 5, wherein said form of cancer associated with breast tissue is selected from inferior ductal carcinoma, inferior lobular carcinoma, intraductal carcinoma, medullary carcinoma and tubular carcinoma.

7. **(Withdrawn)** A method of claim 5, wherein said cancer associated with lung tissue is selected from adenocarcinoma, broncho-alveolar adenocarcinoma and small cell carcinoma.

8. **(Withdrawn)** A method of claim 5, wherein said cancer associated with the prostate is adenocarcinoma.

9. **(Withdrawn)** A method of claim 1, wherein said unwanted cell proliferation is benign prostatic hyperplasia.

10. **(Withdrawn)** A method for determining a treatment protocol comprising,
obtaining a tissue sample from a patient, and
determining levels of *gli* gene expression in said sample,
wherein overexpression of a *gli* gene indicates that treatment with a hedgehog antagonist is appropriate.

11. **(Withdrawn)** A method of claim 10, wherein said *gli* gene is *gli*-1.

12. **(Withdrawn)** A method of claim 11, wherein *gli*-1 expression levels are determined by measuring *gli*-1 transcript levels.

13. **(Withdrawn)** A method of claim 11, wherein said *gli*-1 levels are determined by measuring *gli*-1 protein levels.

14. **(Withdrawn)** A method of stimulating surfactant production in a lung cell comprising contacting said cell with an amount of *hedgehog* antagonist effective to stimulate surfactant production.

15. **(Withdrawn)** A method of stimulating lamellated body formation in a lung cell comprising contacting said cell with an amount of *hedgehog* antagonist effective to stimulate lamellated body formation.

16. **(Withdrawn)** A method of claim 14 or 15, wherein said lung cell is present in the lung tissue of a premature infant.

17. **(Currently amended)** ~~A~~ The method of any one of claims 1 and 2-9, wherein said *hedgehog* antagonist is selected from a small molecule having a molecular weight less than 2000 daltons, a *hedgehog* antibody, a *patched* antibody, a *smoothened* antibody, a mutant *hedgehog* protein, an antisense nucleic acid, and a ribozyme.

18. **(Withdrawn)** A method of claim 17, wherein said small molecule is selected from cyclopamine, compound A, tomatidine, jervine, AY9944, triparanol, compound B and functionally effective derivatives thereof.

19. **(Withdrawn)** A method of determining the likelihood that a cancer will develop in a tissue, comprising
obtaining a tissue sample, and
determining levels of *gli* gene expression in said sample,
wherein overexpression of a *gli* gene indicates an increased likelihood that cancer will develop.

20. **(Withdrawn)** A method of claim 19, wherein said *gli* gene is *gli*-1.

21. **(Currently amended)** A method for treating a tumor in a patient, comprising determining whether the tumor overexpresses a *gli-1* gene and administering to said patient an amount of ~~a *hedgehog* antagonist~~ a hedgehog antibody sufficient to decrease the ~~grow~~ growth and/or proliferation of the tumor, wherein the tumor overexpresses a *gli-1* gene and wherein the tumor is associated with at least one of urogenital, lung, breast, prostate, bladder, or colon cancer.

22. **(Canceled)**

23. **(New)** The method of claim 3, wherein said cancer is associated with one or more of prostate, breast, bladder, and colon tissues.

24. **(New)** The method of claim 3, wherein said cancer is associated with colon tissues.

25. **(New)** The method of claim 21, wherein said tumor is associated with at least one of urogenital, breast, prostate, bladder, or colon tissues.